Clinical Trials Logo

Lymphoma, Mantle-cell clinical trials

View clinical trials related to Lymphoma, Mantle-cell.

Filter by:

NCT ID: NCT06084936 Recruiting - Lymphoma Clinical Trials

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

GLOBRYTE
Start date: October 22, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).

NCT ID: NCT06054776 Recruiting - Clinical trials for Mantle Cell Lymphoma

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Start date: June 10, 2024
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects of acalabrutinib, obinutuzumab, and glofitamab and how well they work together for treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Acalabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers such as mantel cell lymphoma at abnormal levels. This may help keep cancer cells from growing and spreading. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Glofitamab is a class of medications called bispecific antibodies. Bispecific antibodies are designed to simultaneously bind to T cells and cancer cell antigens, leading to T-cell activation, proliferation, and cancer cell death. Giving acalabrutinib, obinutuzumab, and glofitamab together may be a safe and effective treatment for patients with relapsed or refractory mantle cell lymphoma.

NCT ID: NCT06045910 Recruiting - Clinical trials for Lymphoma, Non-Hodgkin

A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies

Start date: January 19, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase I/II multicentre, open-label trial designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of a novel chimeric antigen receptor (CAR) T-cell engager, ALETA-001, administered by intravenous (IV) infusion as a single agent every 2 weeks in patients with relapsed non-Hodgkin lymphoma (NHL) who have failed to optimally respond to prior treatment with anti-CD19 CAR T-cell therapy. This first in human study is divided into 2 parts: a safety lead-in phase (Phase I) and a dose expansion phase (Phase II). Different dose levels of ALETA-001 will be evaluated in Phase I in order to define a recommended dosing level and schedule for Phase II. Phase II will further evaluate the safety, PK and therapeutic activity of ALETA-001.

NCT ID: NCT06043011 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia (CLL)

Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms

RUBIN
Start date: September 27, 2023
Phase:
Study type: Observational [Patient Registry]

The purpose of the project is to set up a national, prospective, longitudinal, multicenter registry platform to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with hematological malignancies in Germany.

NCT ID: NCT06029309 Recruiting - Clinical trials for Mantle Cell Lymphoma

Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma

ZANU-TAFA
Start date: May 3, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The main purpose of this study to find the ideal dose for the combination treatment of Zanubrutinib and Tafasitamab in patients with mantle cell lymphoma. Another purpose is to assess how well the combination treatment works in patients with the study disease.

NCT ID: NCT06026319 Recruiting - Clinical trials for Mantle Cell Lymphoma

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

Start date: October 26, 2023
Phase: Phase 1
Study type: Interventional

This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells. This research study involves the study drugs: - CD79b-19 CAR T cells - Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process

NCT ID: NCT06022029 Recruiting - Bladder Cancer Clinical Trials

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

ON-5001
Start date: October 13, 2023
Phase: Phase 1
Study type: Interventional

A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibitor in patients with advanced solid tumors and lymphomas.

NCT ID: NCT06014762 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

Start date: April 16, 2024
Phase: Phase 1
Study type: Interventional

Phase 1 study comprised of open-label, dose escalation and expansion cohort study of P-CD19CD20-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed/refractory B cell malignancies

NCT ID: NCT06004167 Recruiting - Clinical trials for Mantle Cell Lymphoma

Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)

Start date: January 14, 2024
Phase: N/A
Study type: Interventional

Participants are invited to take part in this research study because they have relapsed (cancer has come back) or refractory (cancer has not responded to treatment) B-cell Lymphoma and will be undergoing CAR T-cell Therapy. This research is being done to see if a new radiation therapy administration schedule will positively impact the logistics, time, cost, and side effects of radiation therapy. In this research study, participants will receive radiation therapy once weekly for 5 weeks. This is a novel administration schedule and we're looking to see how this schedule impacts side effects participants may experience, the time spent receiving radiation therapy, how much radiation therapy participants can receive, and how effective this new schedule is.

NCT ID: NCT05992597 Recruiting - Clinical trials for Rituximab, Lenalidomide, Zebutinib ,Mantle Cell Lymphoma

ZR2 Sequential Immunochemotherapy for Newly Treated MCL

Start date: August 1, 2022
Phase: Phase 2
Study type: Interventional

Patients with newly diagnosed MCL were treated with ZR2 regimen for 3 cycles, followed by 3 cycles of immunochemotherapy, and zebrutinib maintenance therapy for 2 years after the end of induction therapy, in order to improve the remission rate and prognosis of patients with induction therapy.